Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cost-effectiveness of Intensive Blood Pressure Management

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cardiovascular Risk Factors Associated With Venous Thromboembolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Perioperative beta-blocker therapy and risks of adverse events in patients undergoing non-cardiac surgery

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandlingForskning

  2. Simulation-based point-of-care ultrasound training: a matter of competency rather than volume

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of Timing of Aortic Valve Replacement Surgery After Stroke With Risk of Recurrent Stroke and Mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ilana B Richman
  • Michael Fairley
  • Mads Emil Jørgensen
  • Alejandro Schuler
  • Douglas K Owens
  • Jeremy D Goldhaber-Fiebert
Vis graf over relationer

Importance: Among high-risk patients with hypertension, targeting a systolic blood pressure of 120 mm Hg reduces cardiovascular morbidity and mortality compared with a higher target. However, intensive blood pressure management incurs additional costs from treatment and from adverse events.

Objective: To evaluate the incremental cost-effectiveness of intensive blood pressure management compared with standard management.

Design, Setting, and Participants: This cost-effectiveness analysis conducted from September 2015 to August 2016 used a Markov cohort model to estimate cost-effectiveness of intensive blood pressure management among 68-year-old high-risk adults with hypertension but not diabetes. We used the Systolic Blood Pressure Intervention Trial (SPRINT) to estimate treatment effects and adverse event rates. We used Centers for Disease Control and Prevention Life Tables to project age- and cause-specific mortality, calibrated to rates reported in SPRINT. We also used population-based observational data to model development of heart failure, myocardial infarction, stroke, and subsequent mortality. Costs were based on published sources, Medicare data, and the National Inpatient Sample.

Interventions: Treatment of hypertension to a systolic blood pressure goal of 120 mm Hg (intensive management) or 140 mm Hg (standard management).

Main Outcomes and Measures: Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% annually.

Results: Standard management yielded 9.6 QALYs and accrued $155 261 in lifetime costs, while intensive management yielded 10.5 QALYs and accrued $176 584 in costs. Intensive blood pressure management cost $23 777 per QALY gained. In a sensitivity analysis, serious adverse events would need to occur at 3 times the rate observed in SPRINT and be 3 times more common in the intensive management arm to prefer standard management.

Conclusions and Relevance: Intensive blood pressure management is cost-effective at typical thresholds for value in health care and remains so even with substantially higher adverse event rates.

OriginalsprogEngelsk
TidsskriftJAMA Cardiology
Vol/bind1
Udgave nummer8
Sider (fra-til)872-879
Antal sider8
DOI
StatusUdgivet - 1 nov. 2016

ID: 49811588